Glutathione analogues in cancer treatment

Current Oncology Reports

Volumn 6, Issue 2, 2004, Pages 116-122

  Hamilton, David ^a   Batist, Gerald ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 BROMOBENZYLGLUTATHIONE DIESTER; 4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIOXIDANT; CANFOSFAMIDE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME INHIBITOR; ETACRYNIC ACID; ETOPOSIDE; FLUOROURACIL; FREE RADICAL; GLUTATHIONE DERIVATIVE; GLUTATHIONE TRANSFERASE INHIBITOR; LACTOYLGLUTATHIONE LYASE INHIBITOR; MELPHALAN; MITOXANTRONE; OLTIPRAZ; PEROXIDE; PLATINUM DERIVATIVE; PRODRUG; S NITROSOGLUTATHIONE; TAXANE DERIVATIVE; TLK 199; TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; DRUG DERIVATIVE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; LACTOYLGLUTATHIONE LYASE; S 4 BROMOBENZYLGLUTATHIONE CYCLOPENTYL DIESTER; S-4-BROMOBENZYLGLUTATHIONE CYCLOPENTYL DIESTER;

ANEMIA; BLADDER DISEASE; BLOOD TOXICITY; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROTECTION; CLINICAL TRIAL; DRUG DESIGN; DRUG DETOXIFICATION; DRUG ELIMINATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DYSURIA; FATIGUE; HEMATURIA; HUMAN; HYPOKALEMIA; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; OXIDATION REDUCTION REACTION; PANCREATITIS; POLLAKISURIA; REVIEW; THROMBOCYTOPENIA; TUMOR CELL LINE; VOMITING; DRUG ANTAGONISM; NEOPLASM;

GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; LACTOYLGLUTATHIONE LYASE; NEOPLASMS; S-NITROSOGLUTATHIONE;

EID: 2342656304     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0023-4     Document Type: Review

References (64)

1. Adler V, Yin Z, Fuchs SY, et al.: Regulation of JNK signaling by GSTp. EMBO J 1999, 18:1321-1334.
2. Wang T, Arifoglu P, Ronai Z, et al.: Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 2001, 276:20999-21003.
3. Elsby R, Kitteringham NR, Goldring CE, et al.: Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi. J Biol Chem 2003, 278:22243-22249.
4. Yin Z, Ivanov VN, Habelhah H, et al.: Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases. Cancer Res 2000, 60:4053-4057.
5. Sato K: Glutathione transferases as markers of preneoplasia and neoplasia. Adv Cancer Res 1989, 52:205-255.
6. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54:4313-4320.
7. Tew KD, Dutta S, Schultz M: Inhibitors of glutathione S-transferases as therapeutic agents. Adv Drug Deliv Rev 1997, 26:91-104.
8. Paumi CM, Ledford BG, Smitherman PK, et al.: Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance: kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J Biol Chem 2001, 276:7952-7956.
9. Dirven HA, Megens L, Oudshoorn MJ, et al.: Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem Res Toxicol 1995, 8:979-986.
10. Harbottle A, Daly AK, Atherton K, et al.: Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 2001, 92:777-783.
11. Hamilton D, Fotouhi-Ardakani N, Batist G: The glutathione system in alkylator resistance. Cancer Treat Res 2002, 112:67-87.
12. Lyttle MH, Satyam A, Hocker MD, et al.: Glutathione-S-transferase activates novel alkylating agents. J Med Chem 1994, 37:1501-1507.
13. Morgan AS, Sanderson PE, Borch RF, et al.: Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res 1998, 58:2568-2575.
14. Rosario LA, O'Brien ML, Henderson CJ, et al.: Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol 2000, 58:167-174.
15. Townsend DM, Shen H, Staros AL, et al.: Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther 2002, 1:1089-1095.
16. Rosen LS, Brown J, Laxa B, et al.: Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Clin Cancer Res 2003, 9:1628-1638.
17. Papadimitrakopoulou V, Figlin R, Garland G, et al.: Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens [abstract]. Proc ASCO 2003, 22:2636.
18. Washington D, Miller K, Budd GT, et al.: Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) as third-line therapy in patients with advanced metastatic breast cancer (MBC) [abstract]. Proc ASCO 2003, 22:61.
19. Kavanagh JJ, Kudelka AP, Garcia A, et al.: Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory or resistant third-line advanced ovarian cancer [abstract]. Proc ASCO 2003, 22:1816.
20. Morgan AS, Ciaccio PJ, Tew KD, et al.: Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol 1996, 37:363-370.
21. O'Brien ML, Vulevic B, Freer S, et al.: Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 1999, 291:1348-1355.
22. Ruscoe JE, Rosario LA, Wang T, et al.: Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 2001, 298:339-345.
23. Gate L, Lunk A, Tew KD: Resistance to phorbol 12-myristate 13-acetate-induced cell growth arrest in an HL60 cell line chronically exposed to a glutathione S-transferase pi inhibitor. Biochem Pharmacol 2003, 65:1611-1622.
24. Kauvar LM, Morgan AS, Sanderson PE, et al.: Glutathione based approaches to improving cancer treatment. Chem Biol Interact 1998, 111-112:225-238.
25. Mascavage JC, Faderl SH, Kantarjian HM, et al.: TLK199 (novel glutathione analog inhibitor of GST P1-1): phase 1-2a multidose-escalation study in myelodysplastic syndrome (MDS) [abstract]. Proc ASCO 2003, 22:938.
26. Nakajima T, Takayama T, Miyanishi K, et al.: Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethyl-ester. J Pharmacol Exp Ther 2003, 306:861-869.
27. Hamilton D, Wu JH, Alaoui-Jamali M, et al.: A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production. Blood 2003, 102:725-730.
28. Lyon RP, Hill JJ, Atkins WM: Novel class of bivalent glutathione S-transferase inhibitors. Biochemistry 2003, 42:10418-10428.
29. Creighton DJ, Hamilton DS: Brief history of glyoxalase I and what we have learned about metal ion-dependent, enzyme-catalyzed isomerizations. Arch Biochem Biophys 2001, 387:1-10.
30. Thornalley PJ: Advances in glyoxalase research: glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Crit Rev Oncol Hematol 1995, 20:99-128.
31. Sakamoto H, Mashima T, Kizaki A, et al.: Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000, 95:3214-3218.
32. Davidson SD, Milanesa DM, Mallouh C, et al.: A possible regulatory role of glyoxalase I in cell viability of human prostate cancer. Urol Res 2002, 30:116-121.
33. Sakamoto H, Mashima T, Sato S, et al.: Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 2001, 7:2513-2518.
34. Murata-Kamiya N, Kamiya H: Methylglyoxal, an endogenous, aldehyde, crosslinks DNA polymerase and the substrate DNA. Nucleic Acids Res 2001, 29:3433-3438.
35. Rahman A, Shahabuddin Hadi SM: Formation of strand breaks and interstrand cross-links in DNA by methylglyoxal. J Biochem Toxicol 1990, 5:161-166.
36. Himo F, Siegbahn PE: Catalytic mechanism of glyoxalase I: a theoretical study. J Am Chem Soc 2001, 123:10280-10289.
37. Kalsi A, Kavarana MJ, Lu T, et al.: Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem 2000, 43:3981-3986.
38. Allen RE, Lo TW, Thornalley PJ: Purification and characterisation of glyoxalase II from human red blood cells. Eur J Biochem 1993, 213:1261-1267.
39. Thornalley PJ, Edwards LG, Kang Y, et al.: Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo: inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol 1996, 51:1365-1372.
40. Bogdan C: Nitric oxide and the immune response. Nat Immunol 2001, 2:907-916.
41. Ohshima H, Tatemichi M, Sawa T: Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 2003, 417:3-11.
42. Petit JF, Nicaise M, Lepoivre M, et al.: Protection by glutathione against the antiproliferative effects of nitric oxide: dependence on kinetics of no release. Biochem Pharmacol 1996, 52:205-212.
43. Wink DA, Vodovotz Y, Laval J, et al.: The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998, 19:711-721.
44. Vodovotz Y: Control of nitric oxide production by transforming growth factor-beta1: mechanistic insights and potential relevance to human disease. Nitric Oxide 1997, 1:3-17.
45. Dinapoli MR, Calderon CL, Lopez DM: The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med 1996, 183:1323-1329.
46. Cobbs CS, Brenman JE, Aldape KD, et al.: Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995, 55:727-730.
47. Thomsen LL, Lawton FG, Knowles RG, et al.: Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994, 54:1352-1354.
48. Thomsen LL, Miles DW, Happerfield L, et al.: Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995, 72:41-44.
49. Hogg N: The biochemistry and physiology of S-nitrosothiols. Annu Rev Pharmacol Toxicol 2002, 42:585-600.
50. Zeng H, Spencer NY, Hogg N: Metabolism of S-nitrosoglutathione by endothelial cells. Am J Physiol Heart Circ Physiol 2001, 281:H432-H439.
51. Singh RJ, Hogg N, Joseph J, et al.: Mechanism of nitric oxide release from S-nitrosothiols. J Biol Chem 1996, 271:18596-18603.
52. Hogg N, Singh RJ, Kalyanaraman B: The role of glutathione in the transport and catabolism of nitric oxide. FEBS Lett 1996, 382:223-228.
53. Liu Q, Chan ST, Mahendran R: Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis 2003, 24:637-642.
54. Gerke V, Moss SE: Annexins and membrane dynamics. Biochim Biophys Acta 1997, 1357:129-154.
55. Claudio JO, Masih-Khan E, Tang H, et al.: A molecular compendium of genes expressed in multiple myeloma. Blood 2002, 100:2175-2186.
56. Mai J, Sameni M, Mikkelsen T, et al.: Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem 2002, 383:1407-1413.
57. Emoto K, Yamada Y, Sawada H, et al.: Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001, 92:1419-1426.
58. Kim J, Hajjar KA: Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 2002, 7:d341 -d348.
59. Zhang X, Zhou H, Wang J, et al.: Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. Thromb Res 2002, 106:63-70.
60. Liu JW, Shen JJ, Tanzillo-Swarts A, et al.: Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003, 22:1475-1485.
61. Chetcuti A, Margan SH, Russell P et al.: Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 2001, 61:6331-6334.
62. Maxwell PJ, Longley DB, Latif T, et al.: Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003, 63:4602-4606.
63. Liu L, Enright E, Sun P, et al.: Inactivation of annexin II tetramer by S-nitrosoglutathione. Eur J Biochem 2002, 269:4277-4286.
64. Rowan WH, Sun P, Liu L: Nitration of annexin II tetramer. Biochem 2002, 41:1409-1420.